Melanie Cole (Host): There's no handbook for your child's health,
but we do have a podcast featuring world-class clinical and research
physicians covering everything from your child's allergies to zinc levels.
Welcome to Kids Health Cast by Weill Cornell Medicine.
I'm Melanie Colon.
Today we're talking about pediatric diabetes prevention.
joining me is Elizabeth Gunckel.
She's a nurse practitioner and diabetes educator in the division of Pediatric
endocrinology at Weill Cornell Medicine.
Elizabeth, thank you so much for joining us.
Why don't you start by telling us a little bit about diabetes and type one
diabetes, how common it is, really.
Tell us a little bit about what it is.
Dr Elizabeth Gunkle: Yeah.
So, thank you so much for having me.
as a general term, diabetes is focused on the pancreas not making enough insulin.
and when we don't have enough insulin, this leads to high blood sugars.
we typically think about diabetes as.
Two main forms of diabetes, so type one diabetes and type two.
We used to think of type one as being a childhood diabetes and
type two being adult diabetes.
But we've now really realized that we can see either of these
conditions across the lifespan.
Type one diabetes is much rarer than type two.
It's really only about five or 10% of diabetes here in the us.
but type one diabetes is really what we'll be focusing on today because
we've realized we can identify type one diabetes earlier on.
type one diabetes is an autoimmune condition.
So what this means is the immune system sort of inaccurately.
identifies these cells in the body as an invader and So, it.
gradually breaks down these, insulin producing cells in the pancreas,
which lead to these high blood sugars.
And so we identify type one diabetes with these auto antibodies.
So This is what we'll be testing for when we talk about diabetes
screening and prevention.
Melanie Cole (Host): Well, thank you for that.
I'd like you to tell us about the new Diabetes Prevention Program
at Weill Cornell Medicine, which entails type one diabetes screening
for the general population.
Tell us about that.
Dr Elizabeth Gunkle: Yeah, absolutely.
So, we used to think about type one diabetes as somewhat
of a binary diagnosis.
Someone went from having no diabetes to having type one diabetes and needing
insulin, and now we've realized that we can identify these antibodies earlier
on to catch things before someone needs insulin and is, very sick.
So here at Weill Cornell, what we typically.
Offer is, a video visit with me or one of my diabetes colleagues where we can
really go through all the ins and outs of what is type one diabetes, what
are the risk factors for developing type one, how do we screen, et cetera.
And so, our typical process after doing the video visit is
we can offer one of two things.
We either can order these, five commercially available antibodies.
Through Quest or LabCorp or our hospital or, we sometimes will have
families go through our partnership with Barbara Davis Center in Colorado.
They have a program called Ask a SK, so autoimmunity screening for kids.
This is a great, research-based opportunity to do screening
That is outside of insurance, so it's guaranteed to be free.
We generally don't have many issues with insurance coverage through a commercial
lab, but it is, potentially variable.
So we give all of our families both options.
Melanie Cole (Host): That's great.
so you just briefly mentioned another association that are involved
in this initiative and program.
Expand on that just a little bit.
How did that come about?
Dr Elizabeth Gunkle: we were really trying to make sure that
our patient's had access to this valuable information for screening.
And so we wanted to see what sort of partnerships we
could develop for, research opportunities and, Barbara Davis.
their ASK program is really amazing because they actually offer type one
diabetes screening for the general population, which is not overly common.
Many of the other, programs are focused only on people who have a family
history of type one diabetes, whereas Barbara Davis says, you know, we
know family history is a risk factor.
But in reality, almost 90% of patient's who developed Type
one had no family history.
And so they're trying to develop more and more, support to say like, This
is really something that we should be offering to the general population.
Melanie Cole (Host): That's excellent.
And tell us, Elizabeth, about exciting advancements in diabetes prevention
about a medication called tal.
which can actually delay the onset of Type one diabetes.
Really.
Dr Elizabeth Gunkle: honestly, it's, a really, really amazing advancement
and I, you know, I tell my families there's never a time to develop
type one diabetes, but in terms.
The rate of research and new trials and new technology.
This is, a pretty exciting time to be within the field of diabetes.
I do think before, really explaining how top or Tze works, I do wanna
briefly explain what we now know about the different stages of Type
one diabetes, because That is, really where, tze targets its intervention.
So, we used to think.
Life before diabetes And then life with diabetes.
But now we realize that there's this process of how type one diabetes develops.
So we know that someone starts off with some sort of risk factor.
There's then some sort of environmental trigger.
This might be a virus or other things within the environment, but
it kickstarts that immune activation.
And so.
Immune activation is what ultimately leads to those antibodies developing.
And then over time, those antibodies that gradually are breaking
down more and more cells in the pancreas that produce insulin.
And once we get to a critical level, which is usually like 80%
of our cells that are gone, we typically then have those symptoms.
And that's when we were previously being diagnosed with type one diabetes.
So once someone has two antibodies.
They technically have type one diabetes, And then depending on where
the blood sugars are and how someone is feeling, that determines what
stage of type one diabetes they're in.
So there are three stages, all of which, to qualify for.
You initially have to have, again, those two positive antibodies or more,
Stage one means someone is feeling great and blood sugars are totally normal.
Stage two, which is what we're gonna focus on with Umab, is once
the blood sugars are starting to become a little bit abnormal, right?
We have some of those warning signs, but the person's still feeling well.
So it's not something that would otherwise necessarily have been
picked up without screening.
And then stage three is really what we used to think about,
historically, like what classicals.
Type one diabetes is when someone is very sick.
They often are in the hospital and they need, insulin.
So the way that Umab or Tsal works is it focuses on that middle stage.
So stage two, the body's starting to have a hard time keeping up
with those blood sugars, And this medication is A monoclonal antibody.
What that means is that it's working with the cells in the immune system, trying
to protect those cells in the pancreas and trying to reduce inflammation.
The medication is not a cure, but it is, a delay.
And so the goal, and sort of what the research shows is that it can
delay the onset of needing insulin by about two to three years on average.
Melanie Cole (Host): Wow.
Like you said, it's a very exciting time in your field.
That's really cool.
So, who can benefit from this program, as you said, you know, and patient
selection is certainly gonna be an issue.
Tell us about who can join, who can benefit, And what you're doing.
Dr Elizabeth Gunkle: really anyone who's interested is, more than welcome to,
schedule a visit with us And we can meet with them, explain what services we offer.
We, have been generally targeting most of our interventions, for screening with,
people with type one diabetes, family history, or any autoimmune history.
The reason being is because we know that.
People who do have autoimmune conditions or type one diabetes
in the family, they're about 15 times more likely to develop type
one than, the general population.
However, if anyone is interested, we're happy to see them.
We're happy to do the screening.
If the screening shows no antibodies, then we give recommendations on
when we might wanna repeat it.
But if those antibodies are positive, Then you're in a great place.
We have a wonderful team that can explain to you what the next steps
are and, whether we qualify for any of these, medications or trials.
Melanie Cole (Host): Well, you just got right to my next question.
Tell us about your team, Elizabeth, what type of multidisciplinary group
is really involved in the program?
Because, while you're telling us that, I'd like you to speak about the support
that's available for individuals at-risk because that really goes together with the
team approach And that multidisciplinary approach for those with pre-diabetes,
gestational type one or type.
To kind of put that all together for us with this multidisciplinary team.
How many people who's involved?
Dr Elizabeth Gunkle: we have a fantastic team.
We all work so, so closely together.
we are a relatively smaller group compared to a lot of the other,
teams within New York, but I, say we're the mom and pop shop.
one of the few mom and pop shops in Manhattan.
We know all of our, patient's really, really well.
all of our team is very close, so we have three main diabetes attendings.
We have two nurse practitioners, including myself, which, were
both diabetes educators as well.
We have three fellows.
We have a, registered dietician who's also a diabetes educator.
We have a social worker, a psychologist.
we have two amazing nurses.
So we really have excellent multidisciplinary support for our patient.
Melanie Cole (Host): Wow.
You sure do.
Tell us a little bit about some of that support when you're
working with these patient's and.
I have to say, Elizabeth, that when you're working with patient's, especially
our younger kiddos that are growing up to learn how to manage their diabetes,
which is definitely not easy, And then they're transitioning even to adult
care and maybe they've got a glucose monitor and maybe they've got, you
know, all of this technology going on, how do you work with the families?
Because it really has to be a family initiative, doesn't it?
Dr Elizabeth Gunkle: oh, absolutely.
here at Cornell we are.
So individualized with our approach to each of our patient's.
So we, really do try to understand, where someone's at, what other
support do they need with any social services, any psychological services,
but also for their management.
We are of the mindset of.
Of like, why not try something?
Right?
it's not one-size-fits-all.
If our, standard bread and butter approach isn't working, what else can we try?
And so we really pride ourselves in being very individualized in our approach
for management of this condition.
'cause it's, 24 7, right?
365 days a week.
These kids and these families don't have a break from diabetes.
And so whatever we can do to support them, we give 'em our a hundred percent.
Melanie Cole (Host): I am sure you do.
I can hear that in your voice.
Wrap it up for us with your best advice for families and
patient's living with diabetes.
Type one And the amazing program at Weill Cornell Medicine,
Dr Elizabeth Gunkle: just know that you have a huge T 1D community.
There are so many different community resources as well.
But, if you're interested in setting up care with us, we are more than
Happy to screen for any, family members for type one diabetes.
and we do also try to do some community events with our patient's, with
our Type one diabetes, elementary school camp that we do every summer.
We try to do some teens events, as well.
But just really make sure that you lean on, your community
And also your healthcare team.
Melanie Cole (Host): Great information, Elizabeth, thank you so much
for joining us today and sharing your program and your expertise.
That was great information and Weill Cornell Medicine continues to see
our patient's in-person as well as through video visits, and you can
be confident of the safety of your appointments at Weill Cornell Medicine.
That concludes today's episode of Kids HealthCast.
We'd like to invite our audience to download, subscribe, rate, and
review Kids HealthCast on Apple Podcast, Spotify, iHeart, and Pandora.
For more health tips, go to Weill cornell.org
and search podcasts.
And don't forget to check out Back to Health.
We have so many great podcasts there as well.
I'm Melanie Cole.
Thanks so much for joining us today.
Back to Health promo: Back to health is your source for the
latest in health, wellness, and medical care for the whole family.
Our team of world-renowned physicians at Weill Cornell Medicine are having
in-depth conversations covering trending health topics, wellness
tips, and medical breakthroughs.
With the spotlight on our collaborative approach to patient care, the series
will present cutting-edge treatments, innovative therapies, as well as real life
stories that will answer common questions for both patient's and their caregivers.
Subscribe wherever you listen to podcasts.
Also, don't forget to rate us five stars.
disclaimer: All information contained in this podcast is intended for
informational and educational purposes.
The information is not intended nor suited to be a replacement or substitute for
professional medical treatment or for professional medical advice relative to
a specific medical question or condition.
We urge you to always seek the advice of your physician or medical professional
with respect to your medical condition or questions while Cornell Medicine makes
no warranty guarantee or representation as to the accuracy or sufficiency
of the information featured in this podcast, and any reliance on such
information is done at your own risk.
Participants may have consulting, equity, board membership, or other
relationships with pharmaceutical, biotech, or device companies unrelated
to their role in this podcast.
No payments have been made by any company to endorse any
treatments, devices, or procedures.
And while Cornell Medicine does not endorse, approve, or recommend
any product, service, or entity mentioned in this podcast.
Opinions expressed in this podcast are those of the speaker and do not
represent the perspectives of Weill Cornell Medicine as an institution.